• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Natural Cycles Submits FDA Premarket Notification for Wearable Birth Control

Share:

October 23, 2020

Swedish CE-certified birth control app, Natural Cycles has announced that it has submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA).

The Natural Cycles app, is the first and only FDA cleared birth control app in the US.

WHY IT MATTERS

The purpose of the notification is to revise the labeling to expand the third-party thermometers, which include wearables already on the market, which can be used with its app.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

The app is powered by an algorithm that is able to identify a woman’s daily fertility status based on her basal body temperature and other menstrual data.

Currently, users use a standard basal thermometer to take their daily temperature and input that temperature manually into the app.

New software has been developed and added to the Natural Cycles application that converts temperature data received from wearable devices that collect biometric temperature data to a format that can be interpreted by the Natural Cycles algorithm.

This will remove the manual steps of measuring orally and entering temperature data for users who wear an integrated device.

THE LARGER CONTEXT

Last year, Natural Cycles took part in a study that analysed key characteristics of over 600,000 menstrual cycles and data from nearly 125,000 women from Sweden, the UK and the US, to highlight the benefits of understanding their own cycle characteristics rather than relying on a standardised cycle.

The app received FDA clearance to be marketed as the first digital contraception in August of 2018.

The year before, it raised $30 million in a round led by EQT Ventures, bringing the company’s total funding to around $38 million.

ON THE RECORD 

Natural Cycles co-founder and CEO, Elina Berglund Scherwitzl said: “For years we’ve been looking to create a more seamless measuring experience for our users and we were thrilled with the results from using our new software with temperature data from popular wearables.”

“We know our users love having a hormone-free birth control option and we are excited to give them additional measuring options that many already have given a large number of our users own a wearable device.”

Source: Mobi Health News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Insights on the Medical Holography Global Market to 2026 – Key Drivers and RestraintsInsights on the Medical Holography Global Market to 2026 – Key Drivers and Restraints
  • Legato Healthcare Marketing Acquires Fresh Digital MarketingLegato Healthcare Marketing Acquires Fresh Digital Marketing
  • Teladoc Health Expands Partnership with NLA to Offer Whole-Person CareTeladoc Health Expands Partnership with NLA to Offer Whole-Person Care
  • DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology PipelineDelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
  • Sera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, to be acquired by CURE Pharmaceutical in a $20 Million TransactionSera Labs, a Leader in the CBD Industry with Proprietary Products and Multi-Channel Distribution Platform, to be acquired by CURE Pharmaceutical in a $20 Million Transaction
  • Following Restructure, Tocagen Enters Into Reverse Merger with ForteFollowing Restructure, Tocagen Enters Into Reverse Merger with Forte
  • Iktos and Almirall Announce Research Collaboration in Artificial Intelligence for New Drug DesignIktos and Almirall Announce Research Collaboration in Artificial Intelligence for New Drug Design
  • Philips, Spencer Health Launches In-Home Medication Adherence & Telehealth Platform in EuropePhilips, Spencer Health Launches In-Home Medication Adherence & Telehealth Platform in Europe

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications